Compositions and methods for modulating ATP2A2 expression
First Claim
Patent Images
1. A single stranded oligonucleotide produced by a process comprising:
- synthesizing a single stranded oligonucleotide that;
(a) has a sequence 5′
-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 8-23 nucleotides in length,(b) is complementary with at least 15 consecutive nucleotides of a PRC2-associated region of a human ATP2A2 gene, wherein the PRC2-associated region is a region of the ATP2A2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the ATP2A2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and
(c) does not comprise three or more consecutive guanosine nucleotides;
wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue.
7 Assignments
0 Petitions
Accused Products
Abstract
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2.
218 Citations
31 Claims
-
1. A single stranded oligonucleotide produced by a process comprising:
-
synthesizing a single stranded oligonucleotide that; (a) has a sequence 5′
-X-Y-Z, wherein X is any nucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a seed sequence of a human microRNA, and Z is a nucleotide sequence of 8-23 nucleotides in length,(b) is complementary with at least 15 consecutive nucleotides of a PRC2-associated region of a human ATP2A2 gene, wherein the PRC2-associated region is a region of the ATP2A2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the ATP2A2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; and (c) does not comprise three or more consecutive guanosine nucleotides; wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 25, 26, 27, 28, 29, 30, 31)
-
-
23. A single stranded oligonucleotide produced by a process comprising:
-
synthesizing a single stranded oligonucleotide that; (a) comprises a region of complementarity that is complementary with at least 15 consecutive nucleotides of a PRC2-associated region of a human ATP2A2 gene, wherein the PRC2-associated region is a region of the ATP2A2 gene that has a sequence that occurs at a higher frequency in a sequencing reaction of products of an RNA-immunoprecipitation assay that employs an antibody that targets Ezh2 to immunoprecipitate RNA-associated PRC2 complexes from cells comprising the ATP2A2 gene compared to a control sequencing reaction of products of a control RNA-immunoprecipitation assay that employs a control antibody; (b) does not comprise three or more consecutive guanosine nucleotides and has at least one of; i) a sequence that is 5′
X-Y-Z, wherein X is any nucleotide and wherein X is anchored at the 5′
end of the oligonucleotide, Y is a nucleotide sequence of 6 nucleotides in length that is not a human seed sequence of a microRNA, and Z is a nucleotide sequence of 8 to 23 nucleotides in length;ii) a sequence that is complementary to a PRC2-associated region that encodes an RNA that forms a secondary structure comprising at least two single stranded loops; and
/oriii) a sequence that has greater than 60% G-C content wherein, during the synthesis, at least one nucleotide incorporated into the oligonucleotide is a nucleotide analogue. - View Dependent Claims (24)
-
Specification